FaunaBio
Todd Meyerrose is a co-founder of Lexent Bio, specializing in liquid biopsy detection for treatment response since its establishment in 2016 until its acquisition by Roche/Foundation Medicine. As a founding partner at BioMed Ventures since 2015, Todd has invested in numerous innovative companies across various sectors, including Osmind, Synapticure, and Rondo Therapeutics. Additionally, Todd serves as a consulting associate professor at Stanford University, co-directing the Biotechnology Business and Finance course. Advisory roles at ixlayer and Genome Medical, alongside multiple investments in emerging biotech firms, further highlight Todd's dedication to advancing healthcare. Todd holds a PhD in Molecular Cell Biology from Washington University School of Medicine and a PhD in Craniofacial Biology and Development from the University of Southern California, along with a BS in Biology from the University of Kentucky.
This person is not in any teams
This person is not in any offices
FaunaBio
Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bioleverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases.